The invention provides compounds of the formula (I): (I) wherein A.sup.1, A.sup.2, R.sup.2, R.sup.4, B.sup.1, B.sup.2, X, X.sup.1, n, a and b are as defined are defined in the specification, to pharmaceutical compositions comprising the compounds and the compounds for use as medicaments. The compounds potentiate AMPA receptor function and are expected to be useful in the treatment of central nervous system disorders, for example in the treatment of depressive disorders, mood disorders and cognitive dysfunction associated with neuropsychiatric disorders such as schizophrenia.

##STR00001##

The invention provides compounds of the formula (I): (I) wherein A.sup.1, A.sup.2, R.sup.2, R.sup.4, B.sup.1, B.sup.2, X, X.sup.1, n, a and b are as defined are defined in the specification, to pharmaceutical compositions comprising the compounds and the compounds for use as medicaments. The compounds potentiate AMPA receptor function and are expected to be useful in the treatment of central nervous system disorders, for example in the treatment of depressive disorders, mood disorders and cognitive dysfunction associated with neuropsychiatric disorders such as schizophrenia.

##STR00001##

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or prodrug, and/or tautomer, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same. Formula (I).

##STR00001##

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or prodrug, and/or tautomer, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same. Formula (I).

##STR00001##

The subject matter disclosed herein is directed to novel She inhibitors of Formula (II). These compounds are useful for treating impaired insulin sensitivity, glucose tolerance, obesity, diabetes, metabolic syndrome, NAFLD, NASH, PSC, PBC, or other metabolic syndrome component conditions.

##STR00001##

Provided is a compound of Chemical Formula 1: ##STR00001## where A and B each independently is a substituted or unsubstituted aryl group, a substituted or unsubstituted monocyclic or dicyclic heteroaryl group, a substituted or unsubstituted dibenzofuran group, a substituted or unsubstituted benzonaphthofuran group, a substituted or unsubstituted dibenzothiophene group, a substituted or unsubstituted benzonaphthothiophene group, a substituted or unsubstituted phenoxazine group, a substituted or unsubstituted phenothiazine group, a substituted or unsubstituted phenanthroline group, a substituted or unsubstituted benzoquinoline group, a substituted or unsubstituted arylamine group, a substituted or unsubstituted silyl group, or a substituted or unsubstituted phosphine oxide group, or one of the following substituents: ##STR00002## and an organic light emitting device including the same.

Provided is a compound of Chemical Formula 1: ##STR00001## where A and B each independently is a substituted or unsubstituted aryl group, a substituted or unsubstituted monocyclic or dicyclic heteroaryl group, a substituted or unsubstituted dibenzofuran group, a substituted or unsubstituted benzonaphthofuran group, a substituted or unsubstituted dibenzothiophene group, a substituted or unsubstituted benzonaphthothiophene group, a substituted or unsubstituted phenoxazine group, a substituted or unsubstituted phenothiazine group, a substituted or unsubstituted phenanthroline group, a substituted or unsubstituted benzoquinoline group, a substituted or unsubstituted arylamine group, a substituted or unsubstituted silyl group, or a substituted or unsubstituted phosphine oxide group, or one of the following substituents: ##STR00002## and an organic light emitting device including the same.

Provided are an organic electric element comprising as a phosphorescent host material, a mixture of the compounds of Formula (1) and Formula (2), and an organic electronic device or apparatus thereof for achieving a high luminous efficiency, a low driving voltage, and an improved lifespan.

Provided are an organic electric element comprising as a phosphorescent host material, a mixture of the compounds of Formula (1) and Formula (2), and an organic electronic device or apparatus thereof for achieving a high luminous efficiency, a low driving voltage, and an improved lifespan.

The present technology provides 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The 3,3-difluoroallylamines or their pharmaceutically acceptable salts exhibit potent inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).